Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PTX-35 in advanced solid tumors
NCT04430348Phase 1Terminated
- Sponsor
- Pelican Therapeutics
- Start
- Jun 2020
- Primary completion
- Nov 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of PTX-35 in solid tumor (advanced stage) (6 arms), sponsored by Pelican Therapeutics. Primary endpoint: Treatment-emergent Adverse Events at 12 months. Started Jun 2020; status: terminated.
02
Drugs
PTX-35
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT04430348.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04430348.